Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 10/20 | 1.00 |
| ▸ | MTOR | P42345 | 8/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 1.00 |
| ▸ | PIK3C2A | O00443 | 1/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 1/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | ATR | Q13535 | 1/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 1/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 1.00 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 1.00 |
| ▸ | BLK | P51451 | 3/20 | 0.64 |
| ▸ | BMX | P51813 | 3/20 | 0.64 |
| ▸ | JAK3 | P52333 | 3/20 | 0.64 |
| ▸ | BTK | Q06187 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29352777 | 1.00 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3C2APIK3C2B | |
| SCHEMBL30214466 | 1.00 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3C2APIK3C2B | |
| SCHEMBL16730901 | 0.91 | PIK3CA (0.84) | PIK3CAMTORPIK3CDPIK3C2APIK3C2B | |
| SCHEMBL16719230 | 0.90 | PIK3CA (0.82) | PIK3CAMTORPIK3CDPIK3C2APIK3C2B | |
| SCHEMBL18045499 | 0.90 | PIK3CA (0.82) | PIK3CAMTORPIK3CDPIK3C2APIK3C2B | |
| SCHEMBL16730996 | 0.90 | PIK3CA (0.81) | PIK3CAMTORPIK3CDPIK3C2APIK3C2B | |
| SCHEMBL16730997 | 0.90 | PIK3CA (0.81) | PIK3CAMTORPIK3CDPIK3C2APIK3C2B | |
| SCHEMBL22606989 | 0.90 | PIK3CA (0.81) | PIK3CAMTORPIK3CDPIK3C2APIK3C2B | |
| SCHEMBL21552722 | 0.89 | MTOR (0.80) | PIK3CAMTORPIK3CDPIK3C2APIK3C2B | |
| SCHEMBL30925813 | 0.89 | MTOR (0.80) | PIK3CAMTORPIK3CDPIK3C2APIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11471462-B2 | Compositions and methods for detecting and treating diabetes | THE BROAD INSTITUTE, INC. (US) | 2022-10-18 | — | — | US | claimed |
| EP-4729121-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DERMAL DISORDERS | Drexel University (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3352755-B1 | TOPICAL COMPOSITION COMPRISING RAPAMYCIN FOR USE IN TREATING OR PREVENTING SEBORRHEIC KERATOSIS OR ACTINIC KERATOSIS | UNIV DREXEL (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024076670-A2 | TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20230263781-A1 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | PALVELLA THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230263781-A1 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | PALVELLA THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-11679101-B2 | Anhydrous compositions of mTOR inhibitors and methods of use | PALVELLA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679101-B2 | Anhydrous compositions of mTOR inhibitors and methods of use | PALVELLA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2012167606-A1 | PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF | 山东亨利医药科技有限责任公司 (CN) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012167606-A1 | PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF | 山东亨利医药科技有限责任公司 (CN) | 2012-12-13 | — | — | WO | disclosed |
| US-20120190676-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | MOORMAN NATHANIEL (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190676-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | MOORMAN NATHANIEL (US) | 2012-07-26 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011011716-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010044885-A2 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190676-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | EIF2AK2, MTOR, EIF4EBP1 | PIK3CA 501/4885MTOR 2/4885PIK3CD 459/4885 |
| US-20230263781-A1 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | MTOR, RICTOR, RPTOR | PIK3CA 14/4885MTOR 1/4885PIK3CD 59/4885 |
| US-11679101-B2 | Anhydrous compositions of mTOR inhibitors and methods of use | MTOR, RICTOR, RPTOR | PIK3CA 14/4885MTOR 1/4885PIK3CD 59/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | PIK3CA 4614/4885MTOR 1975/4885PIK3CD 3926/4885 |
| US-11471462-B2 | Compositions and methods for detecting and treating diabetes | SLC2A2, SLC2A1, SLC5A2 | PIK3CA 3008/4885MTOR 3599/4885PIK3CD 3504/4885 |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | PIK3CA 36/4885MTOR 1/4885PIK3CD 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.